AbbVie reports $5.94B in worldwide sales for Q3: 4 things to know

AbbVie, the biopharmaceutical company behind hepatitis C drug Viekira Pak, has reported its third quarter 2015 financial results.

Here are four things to know.

1. The company reported $5.944 billion in worldwide sales for the third quarter, an 18.4 percent year-over-year increase.

2. AbbVie's Viekira global sales for the quarter were $469 million. The HCV drug is now approved in 61 countries.

3. The company's net interest expense for the quarter was $197 million.

4. AbbVie's diluted earnings per share for the third quarter were $1.31, up approximately 27 percent.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast